Back to Search
Start Over
Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis.
- Source :
-
Gut microbes [Gut Microbes] 2024 Jan-Dec; Vol. 16 (1), pp. 2356284. Date of Electronic Publication: 2024 May 20. - Publication Year :
- 2024
-
Abstract
- Inflammatory bowel disease (IBD) is a chronic and recurrent condition affecting the gastrointestinal tract. Disturbed gut microbiota and abnormal bile acid (BA) metabolism are notable in IBD, suggesting a bidirectional relationship. Specifically, the diversity of the gut microbiota influences BA composition, whereas altered BA profiles can disrupt the microbiota. IBD patients often exhibit increased primary bile acid and reduced secondary bile acid concentrations due to a diminished bacteria population essential for BA metabolism. This imbalance activates BA receptors, undermining intestinal integrity and immune function. Consequently, targeting the microbiota-BA axis may rectify these disturbances, offering symptomatic relief in IBD. Here, the interplay between gut microbiota and bile acids (BAs) is reviewed, with a particular focus on the role of gut microbiota in mediating bile acid biotransformation, and contributions of the gut microbiota-BA axis to IBD pathology to unveil potential novel therapeutic avenues for IBD.
- Subjects :
- Humans
Animals
Dysbiosis microbiology
Gastrointestinal Tract microbiology
Gastrointestinal Tract metabolism
Gastrointestinal Microbiome
Inflammatory Bowel Diseases microbiology
Inflammatory Bowel Diseases drug therapy
Inflammatory Bowel Diseases metabolism
Bile Acids and Salts metabolism
Bacteria metabolism
Bacteria classification
Bacteria genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1949-0984
- Volume :
- 16
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Gut microbes
- Publication Type :
- Academic Journal
- Accession number :
- 38769683
- Full Text :
- https://doi.org/10.1080/19490976.2024.2356284